CNS Pharmaceuticals logo.png
CNS Pharmaceuticals Featured in Syndicated Broadcast Covering Recent FDA Approval of IND Application
December 28, 2020 08:00 ET | CNS Pharmaceuticals, Inc.
HOUSTON, Dec. 28, 2020 (GLOBE NEWSWIRE) -- via InvestorWire – CNS Pharmaceuticals, Inc. (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary...
CNS Pharmaceuticals logo.png
CNS Pharmaceuticals Featured in Syndicated Broadcast Covering Recent Announcements for Glioblastoma Multiforme (GBM) Therapy
November 24, 2020 08:00 ET | CNS Pharmaceuticals, Inc.
HOUSTON, Nov. 24, 2020 (GLOBE NEWSWIRE) -- via InvestorWire – CNS Pharmaceuticals, Inc. (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary...
CNS Pharmaceuticals logo.png
CNS Pharmaceuticals and Image Analysis Group Partner to Further the Development of Berubicin
September 24, 2020 08:00 ET | CNS Pharmaceuticals, Inc.
HOUSTON, Sept. 24, 2020 (GLOBE NEWSWIRE) -- via NetworkWire -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel...
CNS Pharmaceuticals logo.png
CNS Pharmaceuticals Announces US Drug Manufacturing Milestones
September 03, 2020 08:00 ET | CNS Pharmaceuticals, Inc.
Houston, Texas, Sept. 03, 2020 (GLOBE NEWSWIRE) -- via NetworkWire – CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of...